Takeda Pharmaceutical Company

Diversified pharma / GI

TAK · NYSE · Japan

Share price · TAK

$21.27+3.22 (+17.84%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.4M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TAK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026+4.5%
  2. 17 Jul 2026+2.5%
  3. 2 Jul 2026+5.1%
  4. 1 Jun 2026-4.8%
  5. 22 Apr 2026-2.7%
  6. 10 Feb 2026+2.1%
  7. 29 Jan 2026+2.9%
  8. 23 Jan 2026+2.2%
  9. 8 Jan 2026+3.0%
  10. 23 Dec 2025+2.4%

Share of unusual movement by asset

For each asset, the share of TAK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Fruquintinib (Fruzaqla / Elunate)
events and moves
92%
rusfertide
events and moves
7shown from 8 days
Osavampator
events and moves
4shown from 8 days
zasocitinib
events and moves
4shown from 8 days
vedolizumab (Entyvio)
events and moves
4shown from 8 days
Oveporexton (Orzeyful)
events and moves
4shown from 8 days
IBI363
events and moves
3shown from 8 days
Mezagitamab
events and moves
2shown from 8 days
Sapanisertib
events and moves
2shown from 8 days
maralixibat (Livmarli)
events and moves
2shown from 8 days
Brentuximab Vedotin
events and moves
1shown from 8 days
Cabozantinib
events and moves
1shown from 8 days
TAK-881
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—10%
Other company news (earnings, financing, releases naming no asset)—32%
Sessions with no dated event—55%

Assets

(42 total)
42Total Assets
20Approved
11Phase 3 / Filed
11Phase 1–2 / Early
40Diseases
Quick filter:
Showing 42 of 42 assets
Target & Modality
Alogliptin(Nesina)
Approved
DPP-4Small molecule
Type 2 Diabetes
Approved
ProteasomeSmall molecule
Multiple MyelomaMantle Cell Lymphoma
Approved
Anti-CD30 antibody-drug conjugateAntibody–drug conjugate
Non-Small Cell Lung CancerDiffuse Large B-Cell LymphomaNon-Hodgkin LymphomaCutaneous T-Cell Lymphoma
Large B-Cell Lymphoma, Peripheral T-Cell Lymphoma, High-Grade B-Cell Lymphoma
Approved
ALKSmall molecule
Non-Small Cell Lung Cancer
Approved
MET / VEGFR / AXL / RET (multi-kinase)Small molecule
Non-Small Cell Lung CancerRenal Cell CarcinomaHepatocellular CarcinomaProstate Cancer
Clear Cell Renal Cell Carcinoma
Approved
Myelin basic protein-mimetic immunomodulationPeptide
Multiple Sclerosis
Fruquintinib(Fruzaqla / Elunate)
Approved
VEGFR1/2/3Small molecule
Colorectal CancerRenal Cell CarcinomaEndometrial Cancer
Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer
Approved
ProteasomeSmall molecule
Multiple Myeloma
maralixibat(Livmarli)
Approved
Ileal bile acid transporter (IBAT)Small molecule
Alagille Syndrome
Approved
AminosalicylateSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
AminosalicylateSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
—Antibody–drug conjugate
Ovarian Cancer
Oveporexton(Orzeyful)
Approved
Orexin-2 receptor (agonist)Small molecule
Narcolepsy
Approved
PPAR-gammaSmall molecule
Type 2 Diabetes
Ponatinib(ICLUSIG)
Approved
BCR-ABL (including T315I)Small molecule
Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia

Upcoming events

(72 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (4)
Mirvetuximab soravtansine · ElaherePhase 2High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Est. primary completion 2026-11 · NCT05456685 · CT.gov ↗
What to watch
IBI363Phase 2Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Est. primary completion 2026-11-30 · NCT07122687 · CT.gov ↗
What to watch
TAK-360Phase 2Idiopathic Hypersomnia
Est. primary completion 2026-11-30 · NCT06812078 · CT.gov ↗
What to watch
TAK-360Phase 2Narcolepsy Type 2
Est. primary completion 2026-11-30 · NCT06952699 · CT.gov ↗
What to watch
December 2026 (3)
Oveporexton · OrzeyfulPhase 3Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Est. primary completion 2026-12-17 · NCT07363720 · CT.gov ↗
What to watch
IBI363Phase 2Melanoma
Est. primary completion 2026-12-31 · NCT06797297 · CT.gov ↗
What to watch
IBI363Phase 2Resectable Stage II-III Non-small Cell Lung Cancer
Est. primary completion 2026-12-31 · NCT07402070 · CT.gov ↗
What to watch
2027 (20)
February 2027 (4)
Mirvetuximab soravtansine · ElaherePhase 2Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Est. primary completion 2027-02 · NCT06365853 · CT.gov ↗
What to watch
zasocitinibPhase 2Hidradenitis Suppurativa
Est. primary completion 2027-02-05 · NCT07244263 · CT.gov ↗
What to watch
teduglutide (Gattex)Phase 3Short Bowel Syndrome
Est. primary completion 2027-02-10 · NCT06973304 · CT.gov ↗
What to watch
zasocitinibPhase 2Crohn's Disease
Est. primary completion 2027-02-17 · NCT06233461 · CT.gov ↗
What to watch
March 2027 (2)
Apadamtase alfa · AdzynmaPhase 3Thrombotic Thrombocytopenic Purpura (TTP)
Est. primary completion 2027-03-16 · NCT04683003 · CT.gov ↗
What to watch
zasocitinibPhase 2Nonsegmental Vitiligo
Est. primary completion 2027-03-26 · NCT07108283 · CT.gov ↗
What to watch
April 2027 (1)
Mirvetuximab soravtansine · ElaherePhase 3Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Est. primary completion 2027-04 · NCT05445778 · CT.gov ↗
What to watch
May 2027 (3)
zasocitinibPhase 3Psoriatic Arthritis
Est. primary completion 2027-05-18 · NCT06671483 · CT.gov ↗
What to watch
zasocitinibPhase 3Psoriatic Arthritis
Est. primary completion 2027-05-18 · NCT06671496 · CT.gov ↗
What to watch
zasocitinibPhase 3Palmoplantar Psoriasis
Est. primary completion 2027-05-30 · NCT07752108 · CT.gov ↗
What to watch
June 2027 (1)
vedolizumab · EntyvioPhase 3Crohn's Disease
Est. primary completion 2027-06-08 · NCT06227910 · CT.gov ↗
What to watch
July 2027 (3)
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2027-07 · NCT06786624 · CT.gov ↗
What to watch
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2027-07 · NCT06911112 · CT.gov ↗
What to watch
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2027-07 · NCT06963021 · CT.gov ↗
What to watch
September 2027 (2)
vedolizumab · EntyvioPhase 3Crohn's Disease (CD)
Est. primary completion 2027-09-13 · NCT04779320 · CT.gov ↗
What to watch
vedolizumab · EntyvioPhase 3Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2027-09-24 · NCT03221036 · CT.gov ↗
What to watch
October 2027 (1)
rusfertidePhase 2Polycythemia Vera
Est. primary completion 2027-10-28 · NCT07648030 · CT.gov ↗
What to watch
November 2027 (1)
TAK-360Phase 2Narcolepsy Type 1
Est. primary completion 2027-11-28 · NCT07633301 · CT.gov ↗
What to watch
December 2027 (2)
TAK-411Phase 2Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Est. primary completion 2027-12-02 · NCT06798012 · CT.gov ↗
What to watch
Apadamtase alfa · AdzynmaPhase 2Acute Ischemic Stroke
Est. primary completion 2027-12-06 · NCT07392450 · CT.gov ↗
What to watch
2028 (19)
February 2028 (3)
Ponatinib · ICLUSIGPhase 1/2Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia …
Est. primary completion 2028-02-01 · NCT03934372 · CT.gov ↗
What to watch
ElriterceptPhase 2Myelofibrosis
Est. primary completion 2028-02-28 · NCT05037760 · CT.gov ↗
What to watch
Oveporexton · OrzeyfulPhase 2/3Narcolepsy Type 1
Est. primary completion 2028-02-28 · NCT05816382 · CT.gov ↗
What to watch
March 2028 (2)
MezagitamabPhase 3Immune Thrombocytopenic Purpura (ITP)
Est. primary completion 2028-03-16 · NCT06722235 · CT.gov ↗
What to watch
zasocitinibPhase 2Crohn's Disease
Est. primary completion 2028-03-30 · NCT07403968 · CT.gov ↗
What to watch
May 2028 (2)
TAK-881Phase 3Primary Immunodeficiency Diseases (PID)
Est. primary completion 2028-05-16 · NCT06076642 · CT.gov ↗
What to watch
vedolizumab · EntyvioPhase 3Ulcerative Colitis, Crohn's Disease
Est. primary completion 2028-05-16 · NCT06100289 · CT.gov ↗
What to watch
June 2028 (2)
TAK-881Phase 3Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Est. primary completion 2028-06-25 · NCT06747351 · CT.gov ↗
What to watch
ElriterceptPhase 2Myelodysplastic Syndromes
Est. primary completion 2028-06-26 · NCT07319845 · CT.gov ↗
What to watch
July 2028 (2)
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2028-07 · NCT07196501 · CT.gov ↗
What to watch
rusfertidePhase 2Polycythemia Vera
Est. primary completion 2028-07-01 · NCT07765602 · CT.gov ↗
What to watch
August 2028 (1)
FazirsiranPhase 3Alpha1-Antitrypsin Deficiency
Est. primary completion 2028-08-26 · NCT06165341 · CT.gov ↗
What to watch
September 2028 (3)
SapanisertibPhase 2Endometrial Cancer
Est. primary completion 2028-09 · NCT06463028 · CT.gov ↗
What to watch
MezagitamabPhase 3Kidney Disease
Est. primary completion 2028-09-07 · NCT06963827 · CT.gov ↗
What to watch
ElriterceptPhase 3Myelodysplastic Syndromes
Est. primary completion 2028-09-15 · NCT06499285 · CT.gov ↗
What to watch
October 2028 (2)
IBI363Phase 2Melanoma
Est. primary completion 2028-10-19 · NCT06081920 · CT.gov ↗
What to watch
IBI363Phase 3Colorectal Cancer
Est. primary completion 2028-10-31 · NCT07722494 · CT.gov ↗
What to watch
November 2028 (1)
IBI363Phase 3IO Resistant Squamous and Nonsquamous NSCLC
Est. primary completion 2028-11-01 · NCT07217301 · CT.gov ↗
What to watch
December 2028 (1)
TAK-188Phase 1/2Advanced or Metastatic Solid Tumors
Est. primary completion 2028-12-26 · NCT07205718 · CT.gov ↗
What to watch
2029 (15)
January 2029 (5)
Est. primary completion 2029-01 · NCT07059845 · CT.gov ↗
What to watch
Fruquintinib · Fruzaqla / ElunatePhase 3Advanced Endometrial Cancer
Est. primary completion 2029-01-08 · NCT06584032 · CT.gov ↗
What to watch
maralixibat · LivmarliPhase 2Intrahepatic Cholestasis of Pregnancy
Est. primary completion 2029-01-12 · NCT07823127 · CT.gov ↗
What to watch
MezagitamabPhase 2Antibody-Mediated Rejection (AMR)
Est. primary completion 2029-01-15 · NCT07613359 · CT.gov ↗
What to watch
FazirsiranPhase 3Alpha1-Antitrypsin Deficiency
Est. primary completion 2029-01-17 · NCT05677971 · CT.gov ↗
What to watch
April 2029 (1)
ElriterceptPhase 3Myelodysplastic Syndrome, Anemia
Est. primary completion 2029-04-30 · NCT07422480 · CT.gov ↗
What to watch
May 2029 (2)
SapanisertibPhase 1/2HR+ HER2- Breast Cancer
Est. primary completion 2029-05 · NCT07558733 · CT.gov ↗
What to watch
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2029-05 · NCT06966401 · CT.gov ↗
What to watch
July 2029 (1)
MezagitamabPhase 3Immune Thrombocytopenic Purpura (ITP)
Est. primary completion 2029-07-29 · NCT06948318 · CT.gov ↗
What to watch
August 2029 (1)
zasocitinibPhase 3Plaque Psoriasis
Est. primary completion 2029-08-05 · NCT06550076 · CT.gov ↗
What to watch
September 2029 (1)
Vortioxetine · TrintellixPhase 3Major Depressive Disorder
Est. primary completion 2029-09-30 · NCT07204314 · CT.gov ↗
What to watch
October 2029 (1)
ElriterceptPhase 2Myelodysplastic Syndromes, Cytopenia
Est. primary completion 2029-10-30 · NCT04419649 · CT.gov ↗
What to watch
December 2029 (3)
ElriterceptPhase 3Myelofibrosis, Anemia
Est. primary completion 2029-12-07 · NCT07623161 · CT.gov ↗
What to watch
zasocitinibPhase 3Psoriatic Arthritis
Est. primary completion 2029-12-18 · NCT07286058 · CT.gov ↗
What to watch
zasocitinibPhase 2Crohn's Disease, Ulcerative Colitis
Est. primary completion 2029-12-30 · NCT06764615 · CT.gov ↗
What to watch
2030 (7)
January 2030 (1)
vedolizumab · EntyvioPhase 3Pouchitis
Est. primary completion 2030-01-31 · NCT06443502 · CT.gov ↗
What to watch
February 2030 (1)
Mirvetuximab soravtansine · ElaherePhase 2Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
Est. primary completion 2030-02 · NCT06890338 · CT.gov ↗
What to watch
March 2030 (1)
vedolizumab · EntyvioPhase 3Crohn's Disease
Est. primary completion 2030-03-08 · NCT05837897 · CT.gov ↗
What to watch
April 2030 (1)
zasocitinibPhase 3Psoriatic Arthritis
Est. primary completion 2030-04-18 · NCT07871721 · CT.gov ↗
What to watch
May 2030 (1)
CabozantinibPhase 3Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC) …
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
August 2030 (2)
vedolizumab · EntyvioPhase 3Ulcerative Colitis, Crohn's Disease
Est. primary completion 2030-08-12 · NCT06405087 · CT.gov ↗
What to watch
TAK-505Phase 1/2Malignant Solid Tumors
Est. primary completion 2030-08-18 · NCT07436728 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
TAK-360Phase 2/3Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Est. primary completion 2031-06-15 · NCT07646678 · CT.gov ↗
What to watch
2033 (2)
February 2033 (1)
vedolizumab · EntyvioPhase 3Ulcerative Colitis, Crohn's Disease
Est. primary completion 2033-02-07 · NCT05442567 · CT.gov ↗
What to watch
May 2033 (1)
FazirsiranPhase 3Alpha1-Antitrypsin Deficiency
Est. primary completion 2033-05-02 · NCT05899673 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
zasocitinibPhase 3Plaque Psoriasis
Est. primary completion 2034-07-03 · NCT07250802 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(19)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

Q1 2027FDA action datevedolizumabPDUFA goal date set for Q1 2027
US, FDA · Source ↗

Recent

12 October 2026Topline resultmaralixibatEXPAND Phase 3 topline: primary endpoint met
Mirum Pharmaceuticals, Inc. · Source ↗
14 September 2026Filing acceptedzasocitinibFDA accepts zasocitinib NDA
US, FDA · Takeda · Source ↗
14 September 2026Priority reviewzasocitinibZasocitinib NDA under Priority Review
US, FDA · Takeda · Source ↗
14 September 2026Filing acceptedzasocitinibEMA accepts zasocitinib MAA
EU, EMA · Takeda · Source ↗
September 2026ApprovalApadamtase alfaFDA adds Boxed Warning for neutralizing antibodies to ADAMTS13 to ADZYNMA label
US, FDA · FDA · Source ↗
24 August 2026ApprovalOveporextonORZEYFUL approved in Japan for narcolepsy type 1
JP, MHLW · Source ↗
5 August 2026ApprovalOveporextonFDA approves ORZEYFUL (oveporexton) for narcolepsy type 1
US, FDA · Source ↗
22 July 2026ApprovalOveporextonORZEYFUL (oveporexton) approved in China for narcolepsy type 1
CN, NMPA · Source ↗
9 June 2026Filing acceptedvedolizumabFDA accepts sBLA for IV Entyvio in pediatric UC and Crohn's disease
US, FDA · Source ↗
21 May 2026ApprovalfruquintinibChina approval of ELUNATE plus sintilimab in renal cell carcinoma
China, NMPA · HUTCHMED and Innovent · Source ↗
4 May 2026Topline resultTAK-881Positive topline results from Phase 2/3 TAK-881-3001 trial in PID
2 March 2026Filing acceptedrusfertideFDA accepts rusfertide NDA
US, FDA · Protagonist Therapeutics · Source ↗

The 12 most recent of 18 past events are shown.

Financial reports

Quarterly & interim (10)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$15.2B———report ↗

For H1 FY2025 (ended September 30, 2025), Takeda reported revenue of $15,208.27M, down 2.8% YoY (¥2,219.5B, down 6.9% at actual exchange rates). Reported operating profit was ¥253.6B, down 27.7% YoY, and reported net profit was ¥112.4B, down 40.0% YoY. R&D spend and cash position were not disclosed.

Management updated full-year guidance: core revenue remains broadly flat at CER, while core operating profit and core EPS were revised from broadly flat to low-single-digit percentage declines. Reported full-year forecasts were revised to revenue of ¥4,500.0B, operating profit of ¥400.0B, net profit of ¥153.0B, EPS of ¥97, core EPS of ¥479, and adjusted free cash flow of ¥600.0-700.0B, with annual dividend unchanged at ¥200 per share. The company expects regulatory filings for rusfertide and oveporexton in H2 FY2025, Phase 3 results for zasocitinib, and highlighted a global strategic oncology partnership with Innovent Biologics. The outlook revision reflects FX impacts and impairment losses on the gamma delta T-cell therapy platform.

View 9 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$7.7B———report ↗
2025-H1$15.7B———report ↗
2025-Q1$7.8B———report ↗
2024-H1$14.9B———report ↗
2024-Q1$7.7B———report ↗
2023-H1$14.8B———report ↗
2023-Q1$7.5B———report ↗
2022-H1$16.3B———report ↗
2022-Q1$8.7B———report ↗

Annual history (10 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$27.5B$4.1B——report ↗
View 9 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-9M$22.1B$3.1B$4.2B—report ↗
2025-9M$23.2B———report ↗
2024-FY$29.4B$5.0B$3.0B—$4.9B operating cash flowreport ↗
2024-9M$21.7B———report ↗
2023-FY$29.6B$4.7B$4.0B—$7.2B operating cash flowreport ↗
2023-9M$21.7B———report ↗
2022-FY$31.7B$4.7B$7.0B—$10.0B operating cash flowreport ↗
2022-9M$23.7B———report ↗
2021-FY$30.2B$4.3B$8.8B—$9.6B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 22 sales ($15.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-04Platford Giles Richard · President, IBUOpen-market sale55,617$20.90$1.2MForm 4
2026-11-02Bitetti Teresa Marie · President, OBUOpen-market sale46,609$20.89$974KForm 4
2026-09-14Duprey Lauren Rusckowski · Chief Transformation OfficerOpen-market sale34,535$18.54$640KForm 4
2026-09-02Plump Andrew Stewart · director, President, R&DOpen-market sale116,191$18.49$2.1MForm 4
2026-08-19Plump Andrew Stewart · director, President, R&DOpen-market sale19,651$18.49$363KForm 4
2026-08-18Greenway Nicola Deidre Petal · Chief Human Resources OfficerOpen-market sale12,980$18.11$235KForm 4
2026-08-11Shannon Elaine Mary · Pres., Global Supply & QualityOpen-market sale20,363$17.55$357KForm 4
2026-08-10Greenway Nicola Deidre Petal · Chief Human Resources OfficerOpen-market sale975$17.50$17KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 357 reporting institutions held 98.2M shares ($1.8B, 3.1% of shares outstanding).

#InstitutionSharesValue
1Capital Research Global Investors19,104,219$353.8M
2FMR LLC7,117,486$131.8M
3MORGAN STANLEY6,469,600$119.8M
4ADAGE CAPITAL PARTNERS GP, L.L.C.6,424,984$119.0M
5GOLDMAN SACHS GROUP INC5,618,728$104.1M
6BRANDES INVESTMENT PARTNERS, LP4,430,642$82.1M
7BlackRock, Inc.3,176,421$58.8M
8ARROWSTREET CAPITAL, LIMITED PARTNERSHIP3,116,311$57.7M
9RENAISSANCE TECHNOLOGIES LLC2,989,100$55.4M
10UBS Group AG2,740,229$50.7M
11D. E. Shaw & Co., Inc.2,602,543$48.2M
12FIRST TRUST ADVISORS LP1,971,074$36.5M
13NORTHERN TRUST CORP1,961,038$36.3M
14MANAGED ASSET PORTFOLIOS, LLC1,798,398$33.3M
15ENVESTNET ASSET MANAGEMENT INC1,411,927$26.1M